乙型肝炎核心相关抗原对用nucleos（t）ide类似物治疗的患者肝

StephenW

Journal Summaries in Gastroenterology
Impact of hepatitis B core-related antigen on the incidence of hepatocellular carcinoma in patients treated with nucleos(t)ide analogues

Alimentary Pharmacology and Therapeutics — Hosaka T, et al. | January 22, 2019


In patients with chronic hepatitis B after nucleos(t)ide analogue (NA) therapy, researchers examined if baseline and on-treatment serum hepatitis B core-related antigen (HBcrAg) levels can forecast hepatocellular carcinoma (HCC) incidence. Study participants included 1,268 patients treated with NA therapy for >1 year. For this investigation, serum HBcrAg and hepatitis B surface antigen levels were measured at baseline and 1 year in all patients. One hundred thirteen patients (8.9%) developed HCC (10.3/1,000 person-years) during a median follow-up of 8.9 years. The results obtained from the retrospective cohort study indicate that patients with persistently high on-treatment HBcrAg levels were more likely to develop HCC, in spite of sustained viral suppression through long-term NA treatment.

StephenW

消化内科杂志综述
乙型肝炎核心相关抗原对用nucleos（t）ide类似物治疗的患者肝细胞癌发病率的影响

消化药理学和治疗学 -  Hosaka T，et al。 | 2019年1月22日


在核苷（酸）类似物（NA）治疗后的慢性乙型肝炎患者中，研究人员检查了基线和治疗中血清乙型肝炎核心相关抗原（HBcrAg）水平是否可预测肝细胞癌（HCC）发病率。研究参与者包括1,268名接受NA治疗> 1年的患者。对于该调查，在所有患者的基线和1年测量血清HBcrAg和乙型肝炎表面抗原水平。在中位随访8。9年期间，113名患者（8.9％）发展为HCC（10.3 / 1,000人年）。从回顾性队列研究中获得的结果表明，尽管通过长期NA治疗持续的病毒抑制，持续高治疗HBcrAg水平的患者更可能发展为HCC。

StephenW

https://onlinelibrary.wiley.com/doi/full/10.1111/apt.15108